UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~December~~ May 1114, ~~2010~~ 2012

BIO-BRIDGE SCIENCE, INC.

(Exact name of registrant as specified in its charter)

000-51497

(Commission File Number)

DELAWARE		20-1802936
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

~~1801 South~~PO ~~Meyers~~Box ~~Road~~168081, ~~Suite 220~~Chicago, ~~Oakbrook Terrace,~~ IL, ~~60181~~60616

(Address of Principal Executive Offices, Zip Code)

630-613-9687

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.~~01. Completion~~05 ofCosts ~~Acquisition~~Associated with Exit or ~~Disposition~~Disposal ~~of Assets.~~Activities

~~On December~~In ~~11,~~a ~~2010,~~board ~~Bio-Bridge~~meeting ~~Science~~held ~~(HK)~~on ~~Co.~~May ~~Ltd. (“BBS HK”)~~14th, 2012, a ~~wholly owned~~ majority ~~subsidiary~~of the board directors of Bio-Bridge Science, Inc. ~~(“we”,~~voted ~~“our”),~~to ~~entered~~discontinue ~~into~~operations anof ~~Equity Interest Transfer Contract (“~~the Company due ~~Contract”)~~to lack ~~with~~of ~~China~~funds. The ~~Vaccine~~directors intend ~~Corporation Limited~~to ~~(“China~~recommend ~~Vaccine”),~~ a ~~Hong~~vote ~~Kong~~for ~~company,~~a ~~whereby~~liquidation ~~BBS~~of HKthe ~~agreed~~Company to ~~sell~~the toshareholders. A ~~China~~liquidation ~~Vaccine~~would ~~all~~result ofin the ~~equity~~sale ~~interest we held at our 51% owned subsidiary~~of the Company’s assets, ~~Bio-Bridge~~ ~~Xinheng~~payment ~~Baide~~of ~~Biotechnology~~the ~~Co.~~Company’s ~~Ltd. (“Bio-Bridge XB”)~~creditors, aand ultimately ~~company~~ distribution of ~~the~~ ~~People’s~~any ~~Republic~~remaining ofproceeds ~~China~~to shareholders.

~~China Diamond,~~Item ~~the~~5.02 ~~company~~Departure ~~controlled by one~~ of ~~our~~Directors ~~directors,~~or ~~Trevor~~Certain ~~Roy, also agreed, as a party to the Contract, to sell all of the equity interest (14%) it held at Bio-Bridge XB to China Vaccine.~~Officers

~~The~~On ~~sale price~~May ~~of the combined equity interest (65%) is USD $342~~15th,~~772,~~ ~~or RMB 2~~Dr.3 ~~Million. We~~Liang ~~will~~Qiao ~~receive~~resigned ~~USD~~as ~~$268,944 pro rata~~CEO.

As agreed in the Contract, for the combined equity interest (65%), China Vaccine will pay an earnest money of USD $50,000 within five days after the execution of the Contract, and a second installment of USD $146,386 within six months, and the final installment of USD $146,386 within twelve months, provided certain conditions are met. We will receive the proceeds pro rata.SIGNATURES

APursuant ~~copy~~to the requirements of the ~~Contract~~Securities Exchange isAct ~~filed~~of 1934, as ~~Exhibit~~amended, ~~10.1~~the toRegistrant has duly caused this ~~Form~~report ~~8-K~~to be signed on its behalf by the undersigned hereunto duly authorized.

~~Item 9.01. Financial~~Date: ~~Statements~~May ~~and~~17, ~~Exhibits.~~2012

Exhibit No.		Description
10.1		Equity Interest Transfer Contract

/s/ Dr. Liang Qiao
By: Dr. Liang Qiao
Chairman of Board of Directors

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 15, 2010

/s/ Dr. Liang Qiao By: Dr. Liang Qiao Chief Executive Officer (Principal Executive Officer)

Filing Compare · BIO BRIDGE SCIENCE INC